Sexual health is rarely discussed in performance and wellness content with the same openness as muscle building or fat loss — but for many people, it is one of the most personally significant dimensions of overall wellbeing. Libido, sexual function, and hormonal vitality are closely tied to energy, mood, confidence, and relationship quality. Their decline is one of the earliest and most impactful signals of hormonal imbalance and aging.
The peptides in this stack approach sexual health from multiple angles: central nervous system arousal pathways, upstream hormonal signaling, and the hormonal production machinery itself. Understanding these distinctions is key to choosing the right tool for the specific issue.
What Drives Sexual Health (and What Goes Wrong)
Sexual desire and function depend on a coordinated interaction between the brain, hormones, and vascular system.
Centrally, desire is driven by dopaminergic and melanocortinergic signaling in the hypothalamus — the brain regions that regulate motivation, reward, and arousal. When these pathways are underactive (due to stress, low testosterone, depression, or neurological changes), libido declines regardless of how much testosterone is circulating.
Hormonally, testosterone (in men and women) is the primary driver of libido. LH and FSH from the pituitary signal the gonads to produce it; GnRH from the hypothalamus controls the pituitary. Any dysfunction in this cascade — which is common with aging, overtraining, chronic stress, or hypothalamic suppression — reduces sexual drive and performance.
Vascularly, erectile function in men depends on adequate blood flow to the corpus cavernosum. Traditional medications (PDE-5 inhibitors) address this component but don’t touch the central or hormonal drivers.
The peptides in this stack address all three levels.
The Stack
PT-141 (Bremelanotide)
What it is: PT-141 is the most direct and fast-acting option in this stack for acute sexual function support. A synthetic analog of alpha-MSH, it was originally derived from Melanotan II during research and has since been developed into an FDA-approved medication (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141 is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Research into its use in men and for other sexual health applications is ongoing but represents off-label use outside its approved indication. Any use should be under physician supervision.
Its mechanism is entirely central — it works in the brain, not the blood vessels. This makes it effective in cases where vascular-targeted treatments fall short and gives it a different and often more profound quality of effect.
How it works:
- Activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, stimulating neural pathways directly associated with sexual arousal and motivation
- Works independently of testosterone levels — it can produce arousal even when hormonal levels are suboptimal
- Effects begin within 30–60 minutes and can last 6–12+ hours
- Effective in both men and women through the same central mechanism
What users report: Increased sexual desire and mental arousal — described by many as more motivating and psychologically engaging than PDE-5 inhibitors, which primarily affect the physical response. Men report improved erection quality as a consequence of increased arousal signaling. Women report enhanced desire and sensitivity. Common side effects include transient nausea and flushing, typically dose-dependent.
Typical dosing: 0.5–2 mg subcutaneously, 30–60 minutes before activity. Starting at 0.5–1mg allows for tolerance assessment. Not intended for daily use.
Approximate pricing: $50–$80 per vial. Used on an as-needed basis.
Pricing shown reflects research vendor market rates as of publication. Physician-compounded versions through licensed pharmacies are priced differently and include clinical oversight, quality testing, and prescription fulfillment.
Kisspeptin
What it is: Kisspeptin is a naturally occurring neuropeptide that functions as the master regulator of the reproductive hormone axis. It sits upstream of GnRH — by stimulating the release of Gonadotropin-Releasing Hormone from the hypothalamus, Kisspeptin initiates the hormonal cascade that ultimately drives testosterone (in men) and estrogen/progesterone (in women) production.
Kisspeptin is the target of significant research interest because it represents an upstream intervention: rather than replacing sex hormones directly (as HRT does), it stimulates the body’s own hormonal production machinery.
How it works:
- Binds to KiSS1 receptors in the hypothalamus, triggering GnRH release
- GnRH signals the pituitary to release LH and FSH
- LH stimulates Leydig cells in the testes (men) to produce testosterone; FSH supports sperm production and reproductive function
- In women, the LH and FSH signals regulate ovulation, estrogen production, and cycle regularity
- Also has direct central effects on sexual behavior and attraction that are independent of its hormonal signaling role
Clinical context: Kisspeptin is being actively studied as a treatment for male hypogonadism with preserved testicular function (where the issue is upstream signaling rather than testicular failure), hypothalamic amenorrhea in women, and idiopathic infertility.
What users report: Over a course of several weeks, users pursuing hormonal support report improved libido, mood, energy, and — in men — measurable increases in testosterone when lab-tested. Effects develop more gradually than PT-141 (which is acutely acting); Kisspeptin works through normalizing hormonal production over time.
Typical dosing: 0.5–1 nmol/kg subcutaneously. Protocols vary and are ideally guided by clinical monitoring. Some users dose 2–3x per week; others more frequently.
Approximate pricing: $60–$100 per vial.
Gonadorelin
What it is: Gonadorelin is a synthetic form of GnRH (Gonadotropin-Releasing Hormone) — the hypothalamic signal that triggers pituitary LH and FSH release. While Kisspeptin works one step upstream (triggering endogenous GnRH release), Gonadorelin is GnRH itself.
Gonadorelin is FDA-approved for specific diagnostic and fertility applications, and is widely used in the testosterone replacement therapy (TRT) community as a tool for maintaining testicular function and natural testosterone production during TRT protocols. When exogenous testosterone is administered, the hypothalamus downregulates GnRH production (negative feedback), which causes the testes to shrink and stop producing testosterone. Gonadorelin counters this by providing the GnRH signal externally.
TRT is a physician-supervised medical protocol. Gonadorelin’s use in a TRT context should be directed by the prescribing physician managing that protocol, not self-administered independently.
How it works:
- Directly signals the pituitary to release LH and FSH
- Maintains testicular volume, sperm production, and endogenous testosterone capacity during exogenous testosterone use
- In men not on TRT, can be used to stimulate testosterone production when hypothalamic-pituitary signaling is suboptimal
Important dosing note: Gonadorelin must be administered in a pulsatile fashion to be effective — continuous administration leads to receptor desensitization and actually suppresses LH/FSH. Pulsatile dosing (2–3x per week or more frequently in small doses) mimics the natural pulsatile GnRH pattern.
Typical dosing: 100–200 mcg subcutaneously, 2–3x per week (pulsatile protocol).
Approximate pricing: $40–$70 per vial. Monthly cost approximately $80–$140.
Putting the Stack Together
The right combination in this stack depends on what’s driving the issue.
For acute arousal and immediate sexual function support:
- PT-141 as needed — the most direct and fast-acting tool
For hormonal support and long-term libido optimization:
- Kisspeptin (to stimulate upstream hormonal cascade) or Gonadorelin (if more direct pituitary stimulation is appropriate)
- Combined with lab monitoring of testosterone, LH, and FSH to track response
For men on TRT concerned about testicular health:
- Gonadorelin: 100 mcg 2–3x per week alongside TRT protocol
Combined approach (acute + hormonal):
- PT-141 as needed for situational support
- Kisspeptin 2–3x per week for baseline hormonal optimization
- Monitor via labs every 6–8 weeks
Estimated monthly cost:
- PT-141 only (as-needed use): $50–$80/month or less
- Kisspeptin or Gonadorelin for hormonal support: $80–$150/month
- Full combined stack: $150–$300/month
A Note on Underlying Causes
When libido and sexual function decline significantly — particularly in younger individuals — it’s worth investigating root causes before layering in peptide support. Low testosterone, thyroid dysfunction, elevated prolactin, sleep apnea, chronic stress, and medication side effects (SSRIs, beta-blockers, statins) are all common drivers that may respond to targeted interventions more directly. Lab work is a valuable starting point.
Related Stacks
- Hormonal Support & Longevity — PT-141 and Kisspeptin in the broader hormonal optimization context
- Sleep & Recovery — sleep quality has a profound effect on testosterone and sexual health
- Energy, Focus & Performance — dopaminergic and neurological support that overlaps with drive and motivation
Health Disclaimer
BodyCircuit’s content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed physician before beginning any peptide or wellness protocol. The regulatory status of peptides discussed in this series is evolving — some compounds are FDA-approved, some are expected to return to legal compounding status through physician prescription, and others remain restricted to research use only. BodyCircuit will update this series as regulatory guidance changes. Nothing in this series constitutes an endorsement, recommendation, or offer to sell any compound.
BodyCircuit